Teva Pharmaceuticals names former Sandoz exec to CEO post 

Generics giant Teva Pharmaceuticals (NYSE:TEVA) has named Richard Francis, the CEO of gene therapy company Purespring Therapeutics, as its leader. Purespring Therapeutics is one of the first adeno-associated virus (AAV) gene therapy companies focused on kidney disease.

Francis is also the CEO of the cardiotherapy-focused firm Forcefield Therapeutics, and an operating partner for Syncona Investment Management Ltd.

Teva Pharmaceuticals’s current chief executive Kåre Schultz will retire on December 31, 2022.

Richard Francis

Francis was the division head and CEO of Sandoz, a subsidiary of Novartis (NYSE:NVS), from 2014 to 2019. Before that, he worked at Biogen (Nasdaq:BIIB) for more than 12 years, eventually becoming the president and senior vice president of Biogen, U.S. At Biogen, he was responsible for the commercialization of the multiple sclerosis drug Tecfidera (dimethyl fumarate) in 2013. Sa…

Read more
  • 0

8 drug delivery innovations you need to know

The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon.

Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means.

Among the best innovations in the space are some of the heavy-hitting companies, like Medtronic and Tandem Diabetes Care. Some up-and-comers are beginning to make waves, too, while research continues to uncover new ways to deliver therapeutics.

Here are eight types of drug delivery innovations you should know:

Read more
  • 0